Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Could Your Heartburn Meds Be Giving You Headaches? New Research Reveals Surprising Link

Daniel Kim Views  

The risk of migraines and severe headaches can increase due to the consumption of acid-reducing drugs has been revealed.

The research results suggesting that the risk of migraines and severe headaches can increase due to the consumption of acid-reducing drugs have been published in Neurology Clinical Practice Journal.

Acid reflux generally occurs after meals or when lying down, causing heartburn and potentially leading to peptic ulcers. People who frequently experience acid reflux may develop Gastroesophageal Reflux Disease (GERD), which can potentially lead to esophageal cancer.

The research team noted that acid-reducing drugs are widely prescribed and often overused. The main goal of the research was to precisely assess the impact of these drugs, referring to previous studies suggesting a link between these drugs and various diseases ranging from migraines to dementia.

They analyzed data from 11,818 participants who responded about their use of acid-reducing drugs and whether they had experienced migraines or severe headaches in the previous 90 days.

Of the participants who took Proton Pump Inhibitors (PPI), the most commonly prescribed type of acid-reducing drug, 25% experienced migraines or severe headaches. This percentage was higher than the 19% of participants who did not take PPI and experienced headaches.

Furthermore, 25% of participants who took H2 blockers, a type of acid-reducing drug, experienced severe headaches, while only 20% of participants who did not take H2 blockers experienced severe headaches.

The research team explained that 22% of participants who were taking any acid-reducing drug experienced severe headaches. In comparison, the rate was 20% for those who took no acid-reducing medicines.

They reported that even considering factors such as gender, age, alcohol, and caffeine intake that could influence the risk of migraines, those taking PPI were 70% more likely to experience migraines than those who did not take PPI.

They added that taking H2 blockers and acid inhibitors increased the risk of experiencing migraines by 40% and 30%, respectively.

However, the research team cautioned the limit of this study only suggesting a correlation between acid-reducing drugs and migraines or severe headaches and does not fully explain a causal relationship.

In addition, experts explained that while it is a known fact that there is a correlation between acid-reducing drugs and migraines, it is still unclear whether reducing acid levels has a significant impact on migraines.

They speculated that the central nervous system or glutamate levels, which are part of the pain pathway, could be the link between GERD and headaches.

The researchers also argued that people with high levels of stress tend to produce more stomach acid as a stress response and experience more frequent headaches, which could explain why people taking PPI have a higher rate of headaches. However, experts agreed that because there is a clear correlation between GERD, excessive stomach acid, and migraines, special care is needed when prescribing acid-reducing drugs to patients with migraines.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • What If Rolls-Royce Created a Pickup Truck? A Virtual Rendering Sparks Luxury SUV Curiosity
  • Toyota Reimagines the HiAce with GR Parts: Two Bold Versions for Every Style
  • Study Shows Volunteering Just One Hour a Week Can Slow the Aging Process
  • Rare Pontiac Firebird Trans Am Sells for $60K, Celebrating 30 Years of Muscle Power
  • Dry Air and Nosebleeds: How Winter's Chill Could Be to Blame
  • 5 Health Risks Parents Should Avoid for Their Kids: Experts Weigh In

You May Also Like

  • 1
    Hyundai Ioniq 9: A Game-Changer in Electric SUVs with 331-Mile Range

    BUSINESS 

  • 2
    Dutch Auto Market: Kia EV3 Leads January 2025 Sales

    BUSINESS 

  • 3
    Volkswagen’s Bold Move: Nine New Models and an Affordable EV by 2027

    BUSINESS 

  • 4
    Honda and Nissan End Merger Talks After Two Months of Negotiations

    BUSINESS 

  • 5
    Ford F-150 Loses Best-Selling Title to Toyota RAV4 After 47 Years

    LATEST 

Popular Now

  • 1
    Italdesign Quintessenza Pickup: 2,145 Horsepower and a New Era of Electric Trucks

    BUSINESS 

  • 2
    Kuhl’s Wide-Body Kits Make the Nissan Fairlady Z and Toyota GR Supra Unforgettable

    BUSINESS 

  • 3
    Tesla Model Y Leaks Show Major Changes for China-Specific Version—Here's What You Need to Know

    BUSINESS 

  • 4
    Chevrolet Malibu Could Be Revived as Electric Vehicle in 2025, Rendering Sparks Debate

    BUSINESS 

  • 5
    BYD Surpasses Tesla, Selling 4.1 Million EVs in 2024, Shifting the Global EV Market

    BUSINESS 

Must-Reads

  • 1
    Hyundai Ioniq 9: A Game-Changer in Electric SUVs with 331-Mile Range

    BUSINESS 

  • 2
    Dutch Auto Market: Kia EV3 Leads January 2025 Sales

    BUSINESS 

  • 3
    Volkswagen’s Bold Move: Nine New Models and an Affordable EV by 2027

    BUSINESS 

  • 4
    Honda and Nissan End Merger Talks After Two Months of Negotiations

    BUSINESS 

  • 5
    Ford F-150 Loses Best-Selling Title to Toyota RAV4 After 47 Years

    LATEST 

Popular Now

  • 1
    Italdesign Quintessenza Pickup: 2,145 Horsepower and a New Era of Electric Trucks

    BUSINESS 

  • 2
    Kuhl’s Wide-Body Kits Make the Nissan Fairlady Z and Toyota GR Supra Unforgettable

    BUSINESS 

  • 3
    Tesla Model Y Leaks Show Major Changes for China-Specific Version—Here's What You Need to Know

    BUSINESS 

  • 4
    Chevrolet Malibu Could Be Revived as Electric Vehicle in 2025, Rendering Sparks Debate

    BUSINESS 

  • 5
    BYD Surpasses Tesla, Selling 4.1 Million EVs in 2024, Shifting the Global EV Market

    BUSINESS 

Share it on...